# Ascites Market

> Ascites Market Research Report By Treatment Type (Diuretics, Paracentesis, Albumin Infusion, Transjugular Intrahepatic Portosystemic Shunt, Liver Transplantation, Implantable Ascites Pump Therapy, Palliative Long-Term Abdominal Drainage), By Diagnosis (Physical Examination, Ultrasound, Computed Tomography, Magnetic Resonance Imaging, Diagnostic Paracentesis, Laboratory Testing), By Ascites Type (Refractory Ascites, Recurrent Ascites, Malignant Ascites, Chylous Ascites, Other Ascites Types), By Route of Administration (Oral, Parenteral, Device-Based Delivery), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Home Care Settings, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and By Regional (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 5.6%
- **2025:** USD 2.01 Billion
- **2035:** USD 3.46 Billion
- **Key Players:** Grifols, S.A., CSL Behring, Octapharma AG, W. L. Gore & Associates, Kedrion Biopharma, Pfizer Inc., Merit Medical Systems, Inc., Sequana Medical NV

**Report ID:** MRFR/MED/1377-CR · **Pages:** 130 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** November 16, 2026

**URL:** https://www.marketresearchfuture.com/reports/ascites-market-1909

---

## Market Summary

## Ascites Market Summary

The Ascites Market was valued at USD 2.01 Billion in 2025 and is forecast to reach USD 2.12 Billion in 2026, climbing to USD 3.46 Billion by 2035 at a CAGR of 5.6% over 2026–2035. Two catalysts anchor the outlook. The US Food and Drug Administration granted premarket approval to the first active implantable device for recurrent or refractory cirrhotic ascites in December 2024 [7], and the Centers for Medicare & Medicaid Services followed with a New Technology Add-on Payment worth up to USD 21,450 per inpatient case from October 2025 [11]. Together they move device-led care from European niche to mainstream reimbursement.

Underneath those headlines, clinical practice is evolving. For decades, the treatment of tense or diuretic-resistant ascites necessitated repeated large-volume paracentesis in a hospital day unit, frequently on a two- to three-weekly basis. Continuous drainage through implanted pumps, tunneled palliative catheters that are managed at home, and earlier shunt placement guided by updated consensus criteria are replacing that model [1][3]. The transition is supported by the demand for albumin, which is expected to reach USD 9.5 billion by 2030 [16].

North America maintains a 38.4% revenue share, which is bolstered by its extensive hepatology networks and transplant capacity. Asia-Pacific is the fastest-growing region, with a compound annual growth rate (CAGR) of 7.2%. This growth is primarily due to the increasing prevalence of viral hepatitis and the expansion of tertiary care. Europe is the second-ranked region, with a history of early access to implantable pump therapy and the adoption of long-standing guidelines. Revenue will shift toward technologies that decrease the number of hospital visits per patient over the next decade.

## Key Report Takeaways

### • By Treatment Type

- The albumin infusion segment holds a 27.4% share of Ascites Market treatment revenue, reflecting its role in every large-volume tap protocol.
- The implantable ascites pump therapy segment is the fastest-growing treatment, expanding at a 9.6% CAGR through 2035
- The paracentesis segment generated USD 0.28 Billion in 2025, still the procedural backbone of care.

### • By Diagnosis

- The ultrasound segment accounts for 30.8% of diagnostic revenue as the first-line confirmation tool.
- The magnetic resonance imaging segment grows at a 7.4% CAGR as malignant and chylous workups intensify.

### • By Ascites Type

- Refractory Ascites commands a 43.4% share of the Ascites Market, driven by repeated procedures and inpatient stays
- Malignant Ascites is the fastest-growing type at a 7.1% CAGR, propelled by intraperitoneal immunotherapy pipelines

### • By Route Of Administration

- Parenteral holds 58.6% of revenue, anchored by intravenous albumin
- Device-Based Delivery expands at a 7.9% CAGR, the fastest route

### • By End User

- Hospitals represent a 55.8% share, managing the heaviest clinical burden
- Home Care Settings grow at a 7.3% CAGR as palliative drainage moves out of wards

### • By Distribution Channel

- The hospital pharmacies segment captures 57.6% of channel revenue
- The online pharmacies segment posts a 7.4% CAGR on chronic oral diuretic refills

### • By Region

- North America leads the Ascites Market with a 38.4% share
- Asia-Pacific grows fastest at a 7.2% CAGR
- Europe generated USD 0.58 Billion in 2025

## Market Size and Forecast (2021–2035)

Ascites Market estimates combine procedure volumes from hospital discharge datasets, albumin and diuretic consumption reported by plasma fractionators and pharmaceutical suppliers, device shipment disclosures, and epidemiological inputs on cirrhosis and malignant effusion prevalence [5][6]. Bottom-up treatment counts were reconciled against top-down revenue from 30-plus suppliers, then validated through interviews with hepatologists, interventional radiologists, and hospital procurement leads.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising cirrhosis burden from MASLD and alcohol | +1.2% | Global | Long-term (≥4 yr) | [5][18] |
| Reimbursed implantable pump commercialisation | +0.9% | North America, Europe | Short-term (≤2 yr) | [7][11] |
| Guideline-backed albumin use with large-volume taps | +0.8% | Global | Medium-term (2–4 yr) | [1][2][4] |
| Viral hepatitis burden in emerging economies | +0.6% | Asia-Pacific, MEA | Long-term (≥4 yr) | [6] |
| Intraperitoneal therapy pipeline for malignant disease | +0.5% | Asia-Pacific, Global | Medium-term (2–4 yr) | [13][14] |
| Imaging-guided procedural standardisation | +0.4% | Global | Short-term (≤2 yr) | [1][3] |

### Rising Cirrhosis Burden from MASLD and Alcohol

Cirrhosis caused 1.32 million deaths worldwide in 2017, and age-standardised prevalence keeps rising in high-income regions [5]. Metabolic dysfunction-associated steatotic liver disease now affects roughly 30% of adults globally [18], creating a long pipeline of patients who will eventually decompensate. Ascites is typically the first decompensating event, so each cohort that progresses translates directly into diuretic prescriptions, diagnostic taps, and eventual procedural care.

### Reimbursed Implantable Pump Commercialisation

The US approval of the alfapump in December 2024 rested on the POSEIDON pivotal study of 69 patients across 18 North American centres [7]. CMS then approved an inpatient add-on payment of up to USD 21,450 on top of the standard diagnosis-related group payment [11]. That reimbursement closes much of the cost gap hospitals faced and lets transplant centres justify implant programmes for patients who would otherwise need taps every few weeks.

### Guideline-Backed Albumin Use with Large-Volume Taps

Society guidance recommends 6–8 g of albumin per litre removed when more than five litres are drained, to prevent post-paracentesis circulatory dysfunction [1][2]. The ANSWER trial reported a 38% reduction in mortality with long-term weekly albumin in uncomplicated ascites [4]. These recommendations make albumin a recurring, high-value line item in every hospital that performs therapeutic paracentesis.

### Viral Hepatitis Burden in Emerging Economies

An estimated 304 million people were living with chronic hepatitis B or C in 2022, and viral hepatitis caused 1.3 million deaths that year [6]. China, India, Egypt, and Southeast Asian countries carry a disproportionate share. As screening improves and tertiary hospitals multiply, more patients reach diagnosis at the decompensated stage, lifting demand for imaging, laboratory panels, and albumin across Asia-Pacific and the Middle East.

### Intraperitoneal Therapy Pipeline for Malignant Disease

A randomised Phase II trial of the EpCAM×CD3 bispecific antibody M701 extended median puncture-free survival to 75 days versus 25 days with drainage alone [14]. A 270-patient Phase III study is randomising patients 2:1 against paracentesis [13]. Success would convert malignant ascites from a palliative drainage problem into a drug-treatable indication with premium pricing.

### Imaging-Guided Procedural Standardisation

Updated guidance favours ultrasound guidance for paracentesis and earlier pre-emptive shunt evaluation for selected patients [1][3]. Standardised protocols increase the number of imaging touchpoints per patient, from initial grading through procedural planning and follow-up. Hospitals adopting checklists also report fewer complications, which supports higher procedure throughput in day-case units.

## Restraints

## Restraints Impact Analysis

Restraint impacts on the Ascites Market are directional and overlapping. They indicate drag on growth rather than additive subtractions from the CAGR.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Plasma supply limits and albumin pricing | −0.6% | Global | Medium-term (2–4 yr) | [16] |
| Scarcity of donor livers | −0.5% | Global | Long-term (≥4 yr) | [19] |
| Limited hepatology access in low-income settings | −0.4% | Asia-Pacific, MEA, South America | Long-term (≥4 yr) | [6] |
| Implant eligibility and complication management | −0.4% | North America, Europe | Short-term (≤2 yr) | [22] |
| Mixed evidence on long-term albumin | −0.3% | North America, Europe | Short-term (≤2 yr) | [17] |

### Plasma Supply Limits and Albumin Pricing

Albumin is fractionated from donated plasma, and demand across surgery, sepsis, and liver care is rising faster than new collection capacity in many regions [16]. Supply shocks raise hospital acquisition costs and push some health systems toward stricter albumin stewardship. That rationing directly caps volume growth in the largest treatment segment.

### Scarcity of Donor Livers

Official data from the US Health Resources and Services Administration (HRSA) and OPTN confirm that US centers performed a record 10,659 liver transplants in 2023. Despite this milestone, the active waiting list consistently exceeds 10,000 candidates, while over 1,100 candidates die or become too sick for transplantation annually. Because liver transplantation represents the sole curative therapy for refractory ascites, graft shortages force the vast majority of decompensated patients onto extended palliative pathways utilizing serial paracentesis and medical management.

### Limited Hepatology Access in Low-Income Settings

The WHO Global Hepatitis Report highlights a stark global diagnostic gap: of the estimated 304 million people living with chronic hepatitis B and C, less than 15% have been formally diagnosed. In low- and lower-middle-income countries across sub-Saharan Africa and South Asia, [clinical diagnostic](https://www.marketresearchfuture.com/reports/clinical-diagnostic-market-41770) coverage falls below 5%. Without specialist hepatologists or diagnostic ultrasound equipment, patients frequently present at advanced decompensation stages, relying on basic oral diuretics rather than advanced procedural care or human albumin.

### Implant Eligibility and Complication Management

A European randomised trial of the alfapump found fewer paracenteses but more serious adverse events tied to renal function and device issues than large-volume taps [22]. Patients must meet renal, infection, and anatomical criteria, narrowing the eligible pool. Centres also need trained teams for programming and catheter management, slowing roll-out beyond specialist hubs.

### Mixed Evidence on Long-Term Albumin

Top-line results from the landmark Phase III PRECIOSA trial (NCT03451292), presented at the EASL Congress in May 2025, revealed a neutral primary endpoint for long-term human albumin administration. While the ANSWER trial previously demonstrated survival benefits in uncomplicated ascites, PRECIOSA showed no statistically significant improvement in 1-year transplant-free survival among high-risk decompensated cirrhotic patients. Commercial payers cite this trial variance to deny reimbursement for chronic outpatient albumin maintenance regimens.

## Opportunities

## Ascites Market Opportunities

### Home-Based Palliative Drainage Programmes

Tunnelled abdominal catheters let patients with end-stage disease drain fluid at home with community nursing support. Suppliers that bundle catheters, drainage bottles, and nurse training into a single service contract can capture recurring revenue as Home Care Settings expand. National [palliative care](https://www.marketresearchfuture.com/reports/palliative-care-market-6336) frameworks in the UK and Australia already fund similar models for malignant effusions, creating a template for cirrhotic patients.

### Emerging-Market Hepatology Build-Out

WHO reports confirm that the Asia-Pacific region accounts for over 60% of the world’s 304 million chronic hepatitis cases, combined with rising adult MASLD prevalence (~30%). In response, hospitals across India and Indonesia are expanding hepatology units. Public insurance programs—including India’s Ayushman Bharat PM-JAY (covering up to ₹500,000 USD 6,000 annually per family for over 550 million citizens) and Indonesia's BPJS Kesehatan—now reimburse inpatient liver interventions, driving demand for low-cost paracentesis kits and point-of-care ultrasound.

### Device Telemetry and Outcomes-Based Contracting

Implantable pump telemetry captures continuous daily drainage volumes and battery metrics, providing real-time physiological indicators of fluid accumulation. Manufacturers can monetize this continuous data through remote patient monitoring (RPM) services using CMS reimbursement codes (CPT 99453/99454). According to US Department of Health and Human Services (HHS) pilot evaluations, remote device tracking reduces 30-day hospital readmissions by up to 38%, supporting value-based contracts that tie device payments directly to avoided inpatient admissions.

### Drug-Based Control of Malignant Ascites

Malignant ascites complicates end-stage gastric, ovarian, and colorectal cancers. In May 2026, China’s National Medical Products Administration (NMPA) formally accepted the New Drug Application (NDA) for YZY Biopharma's EpCAM×CD3 bispecific antibody M701. Phase III data presented at ASCO 2026 showed M701 extended median puncture-free survival to 87.59 days versus 49.96 days with paracentesis alone. Approval opens a path for targeted intraperitoneal biologic therapies, offering a premium-priced alternative to palliative drainage

### Integrated Diagnostic Panels

Combining ascitic fluid analysis with cytology, cell counts, and culture in one ordered panel shortens time to differential diagnosis. Laboratory vendors can package reagents, software, and reporting templates for hepatology units, raising the value of each diagnostic tap.

## Future Outlook

## Ascites Market Future Outlook

###  

## Segment Insights

## Ascites Market Segmentation

### By Treatment Type

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| diuretics | 15.2% share | First-line sodium and fluid control |
| paracentesis | USD 0.28 Billion | Tense and refractory fluid removal |
| albumin infusion | 27.4% share | Post-tap volume support |
| transjugular intrahepatic portosystemic shunt | 6.1% CAGR | Earlier shunt selection under consensus criteria |
| liver transplantation | USD 0.15 Billion | Only curative pathway |
| Implantable ascites pump therapy | 9.6% CAGR | US approval and NTAP reimbursement |
| Palliative long-term abdominal drainage | 7.0% CAGR | Home-based end-of-life care |

Treatment accounts for 63.8% of total Ascites Market revenue in 2025. Within it, albumin infusion leads because every large-volume tap triggers a weight-based dose, making it the highest-value consumable per procedure. Paracentesis remains the procedural backbone. Implantable ascites pump therapy grows fastest as transplant centres adopt the Alfapump under new Medicare payments. At the same time, palliative drains benefit from home care funding and patient preference for fewer hospital visits.

### By Diagnosis

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| physical examination | 7.5% share | Initial detection of shifting dullness |
| ultrasound | 30.8% share | First-line confirmation and tap guidance |
| computed tomography | USD 0.13 Billion | Malignancy and loculation assessment |
| magnetic resonance imaging | 7.4% CAGR | Detailed hepatic and peritoneal imaging |
| diagnostic paracentesis | 6.6% CAGR | Mandatory tap on new-onset ascites |
| laboratory testing | USD 0.14 Billion | Cell count, albumin gradient and culture panels |

Diagnosis grows at a 6.4% CAGR, outpacing treatment within the Ascites Market. Ultrasound dominates because it confirms fluid, grades volume, and guides needle placement in one inexpensive step. Magnetic resonance imaging expands fastest as oncology and hepatology teams use it to characterise malignant and chylous causes. Diagnostic paracentesis rises in step with guidance that every hospitalised patient with ascites should be tapped to exclude infection [1].

### By Ascites Type

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Refractory Ascites | 43.4% share | Repeat taps, albumin and inpatient stays |
| Recurrent Ascites | USD 0.52 Billion | Frequent diuretic adjustment and taps |
| Malignant Ascites | 7.1% CAGR | Intraperitoneal antibody pipeline |
| Chylous Ascites | 4.6% share | Post-surgical and lymphatic causes |
| Other Ascites Types | USD 0.11 Billion | Cardiac, renal and infectious causes |

Within the Ascites Market, Refractory Ascites leads because patients who no longer respond to diuretics require taps every few weeks, each with albumin and monitoring. One-year survival in this group is roughly 50%, keeping care intensive [2]. Malignant Ascites grows fastest as bispecific antibodies such as M701 seek to suppress fluid formation directly, creating drug revenue on top of drainage [14].

### By Route Of Administration

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Oral | USD 0.50 Billion | Spironolactone and loop diuretics |
| Parenteral | 58.6% share | Intravenous albumin and antibiotics |
| Device-Based Delivery | 7.9% CAGR | Implanted pumps and tunnelled drains |

Parenteral therapy leads the Ascites Market by route because intravenous albumin accompanies most therapeutic taps and hospital admissions for complications. Oral therapy has high patient volume but low unit value, as generic diuretics dominate. Device-Based Delivery grows fastest, combining implantable pumps with tunnelled catheters that move fluid removal away from repeated needle procedures and toward continuous management.

### By End User

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | 55.8% share | Complex inpatient and interventional care |
| Ambulatory Surgical Centers | USD 0.29 Billion | Elective day-case paracentesis |
| Specialty Clinics | 16.4% share | Hepatology follow-up and diuretic titration |
| Home Care Settings | 7.3% CAGR | Palliative drains and telehealth |
| Others | USD 0.07 Billion | Hospices and long-term care facilities |

Hospitals dominate Ascites Market demand because they manage infections, kidney complications, implant procedures, and transplants under one roof. They also control formulary decisions for albumin and drainage kits. Home Care Settings grow fastest as palliative long-term drains and remote monitoring let stable patients avoid repeated day-unit visits, and Specialty Clinics retain a steady role in diuretic titration.

### By Distribution Channel

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| hospital pharmacies | 57.6% share | Albumin and inpatient drug dispensing |
| retail pharmacies | USD 0.51 Billion | Chronic oral diuretic refills |
| online pharmacies | 7.4% CAGR | Home delivery for chronic patients |
| others | 5.3% share | Specialty distributors and home care suppliers |

Hospital pharmacies lead the Ascites Market's channels because albumin, intravenous antibiotics, and procedure kits are dispensed at the point of care. Retail pharmacies serve the large outpatient population on spironolactone and furosemide. Online pharmacies grow fastest as patients with mobility limits and frequent refills shift to home delivery, a trend reinforced by e-prescribing in the US, India, and China.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 38.4% share | Implant programmes at transplant centres; albumin stewardship |
| Europe | USD 0.58 Billion | Guideline-driven TIPS; home palliative drainage |
| Asia-Pacific | 7.2% CAGR | Hepatitis B burden; tertiary hospital expansion |
| South America | 5.8% share | Alcohol-related cirrhosis; public hospital procurement |
| Middle East & Africa | USD 0.10 Billion | Hepatitis C legacy; Gulf specialty hospitals |
| Total | USD 2.01 Billion | — |

The Ascites Market shows a clear hierarchy: mature, reimbursed procedural care in North America and Europe, and faster volume growth in Asia-Pacific where disease burden outpaces current treatment capacity.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| US | 84.6% share of region | NTAP-supported implant adoption |
| Canada | 5.8% CAGR | Provincial liver programmes and POSEIDON sites |
| Mexico | USD 0.04 Billion | High alcohol-related and MASLD cirrhosis burden |

US providers dominate regional revenue on the back of high albumin consumption, well-funded transplant centres, and Medicare coverage for inpatient procedures. Sequana Medical moved into a US soft launch in the second half of 2025, targeting at least 70 commercial implants before a full launch in Q2 2026 [12]. Canada contributed POSEIDON trial sites and benefits from structured provincial hepatology networks. Mexico has one of the highest cirrhosis mortality rates in the Americas, driving demand for diuretics and paracentesis in public hospitals.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 22.1% share of region | Large hospital base and early pump adoption |
| UK | USD 0.09 Billion | NHS palliative drain pathways |
| France | 15.3% share of region | Strong TIPS expertise |
| Italy | 5.2% CAGR | Long-term albumin practice following ANSWER |
| Spain | USD 0.05 Billion | Hepatology research centres and albumin supply |
| Nordic Countries | 5.6% CAGR | Alcohol-related liver disease screening |
| Russia | 5.4% share of region | Viral hepatitis burden |
| Rest of Europe | USD 0.07 Billion | EU hospital modernisation funds |

Europe's share of the Ascites Market reflects the longest history with implantable pump therapy, which carried CE marking years before US approval. Clinical practice follows EASL guidelines that formalise albumin use and TIPS selection [2]. Italy's adoption of long-term albumin after the ANSWER trial illustrates how national evidence shifts spending [4]. Germany and France lead in shunt procedures, while the UK has piloted community-managed palliative drains.

### Asia-Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 36.2% share of region | Hepatitis B prevalence; domestic biologics |
| India | 8.6% CAGR | Alcohol and MASLD cirrhosis; insurance expansion |
| Japan | USD 0.10 Billion | Ageing population and imaging density |
| South Korea | 7.0% CAGR | Living-donor transplant programmes |
| ASEAN | 8.9% share of region | Hepatitis B and C screening drives |
| Rest of Asia-Pacific | USD 0.03 Billion | Australian palliative care funding |

China carries the world's largest hepatitis B population and a fast-growing domestic biotech sector, with M701 advancing toward approval for malignant ascites [25]. India's public health insurance scheme now covers inpatient liver care for hundreds of millions, lifting procedure volumes. Japan and South Korea combine high imaging capacity with established living-donor transplant programmes, keeping per-patient spending high.

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 52.4% share of region | Unified Health System hepatology centres |
| Argentina | 5.9% CAGR | Transplant activity in Buenos Aires hubs |
| Rest of South America | USD 0.03 Billion | Alcohol-related liver disease in Andean countries |

Brazil's public health system funds paracentesis, albumin, and transplantation through regional reference centres, giving it more than half of regional revenue. Argentina runs one of the region's most active liver transplant programmes. Elsewhere, limited specialist availability keeps treatment centred on oral diuretics and hospital taps.

### Middle East & Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 24.6% share of region | Vision 2030 specialty hospital investment |
| UAE | 7.8% CAGR | Medical tourism and transplant capacity |
| South Africa | USD 0.02 Billion | Private hospital networks |
| Egypt | 7.5% CAGR | Legacy hepatitis C cirrhosis cohort |
| Rest of MEA | 28.3% share of region | Limited but rising tertiary access |

Gulf states are investing in specialist liver units and transplant programmes, pulling advanced procedures into the region. Egypt cured millions of hepatitis C infections through its national programme, yet a large cohort with established cirrhosis still faces decompensation [6]. Sub-Saharan Africa remains underserved, with care largely limited to diuretics and basic drainage.

## Competitive Benchmarking

## Competitive Benchmarking

The Ascites Market is moderately concentrated, with an estimated Herfindahl-Hirschman Index of around 650. The top five suppliers hold roughly 44% of revenue, led by plasma fractionators whose albumin franchises dominate treatment spending. The remainder is fragmented across device makers, generic diuretic producers, and pipeline biotechs, giving smaller innovators room to win share in device-based and malignant segments.

| Company | Est. Revenue Share Range | Key Offerings for Ascites Market | Strategic Positioning |
| --- | --- | --- | --- |
| Grifols, S.A. | ~11–14% | Albutein human albumin | Plasma collection scale; long-term albumin research |
| CSL Behring | ~10–13% | AlbuRx, Albuminar albumin | Global fractionation leader |
| Takeda Pharmaceutical Company Limited | ~6–9% | Flexbumin, Buminate albumin | Broad hospital contracting |
| Octapharma AG | ~5–8% | Albunorm, Octalbin albumin | European hospital strength |
| Becton, Dickinson and Company | ~5–8% | PleurX peritoneal catheter, Safe-T-Centesis kits | Home drainage and procedural kits |
| W. L. Gore & Associates | ~4–7% | GORE VIATORR TIPS Endoprosthesis | Covered-stent leader for shunts |
| Kedrion Biopharma | ~3–5% | Kedbumin albumin | Growing US plasma footprint |
| Pfizer Inc. | ~2–4% | Aldactone (spironolactone) | Branded diuretic heritage |
| Merit Medical Systems, Inc. | ~2–4% | Aspira peritoneal drainage system | Interventional and home drainage |
| Sequana Medical NV | ~1–3% | Alfapump implantable system | First-mover in implantable pumps |
| Wuhan YZY Biopharma Co., Ltd. | <1% | M701 bispecific antibody (pipeline) | Malignant ascites innovator |

## Recent News & Developments

## Recent News & Developments

- Sequana Medical (January 2024): The FDA accepted the alfapump PMA application for substantive review, confirming the file was complete and starting the final regulatory phase for the first US implantable ascites device [9]
- Madrigal Pharmaceuticals / FDA (March 2024): The FDA approved the first therapy for MASH with moderate-to-advanced fibrosis, a long-term upstream lever on future cirrhosis and ascites incidence
- FDA / Sequana Medical (December 2024): The alfapump received premarket approval for recurrent or refractory ascites due to cirrhosis, creating a new device category in the US [7][8]
- Wuhan YZY Biopharma (December 2024): Updated Phase II M701 data at ESMO Asia showed puncture-free survival benefit across gastric, colorectal, and ovarian cancers, supporting the ongoing Phase III
- Grifols (May 2025): Full PRECIOSA results presented at EASL showed a neutral primary endpoint for long-term albumin, though investors and clinicians continue to study subgroup signals [17]
- Centers for Medicare & Medicaid Services (August 2025): The FY2026 inpatient final rule approved an add-on payment of up to USD 21,450 for alfapump cases, effective October 2025 [11][21]
- Novo Nordisk / FDA (August 2025): Semaglutide received accelerated approval for MASH with moderate-to-advanced fibrosis, broadening the upstream treatment toolkit [23]
- Sequana Medical (September 2025): US soft launch began, targeting at least 70 commercial implants ahead of full launch in Q2 2026 [12]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Treatments, diagnostics, devices and drugs for ascites delivered through hospital, retail and online channels to hospitals, ambulatory, clinic and home care users |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 2.01 Billion |
| Market Size in 2035 | USD 3.46 Billion |
| CAGR (2026–2035) | 5.6% |
| Fastest Growing Segments | Implantable ascites pump therapy (9.6% CAGR); Device-Based Delivery (7.9% CAGR); online pharmacies (7.4% CAGR); Home Care Settings (7.3% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Grifols S.A., CSL Behring, Takeda Pharmaceutical Company Limited, Octapharma AG, Becton Dickinson and Company, W. L. Gore & Associates, Kedrion Biopharma, Pfizer Inc., Merit Medical Systems Inc., Sequana Medical NV, Wuhan YZY Biopharma Co. Ltd. |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: What procedure codes support implantable pump billing in the Ascites Market?**
A: The American Medical Association issued six Category III CPT codes for AlphaPump-related procedures, supplementing existing ICD-10 codes [8]. Category III codes track emerging technology, so commercial payer coverage still varies case by case.

**Q: Which laboratory thresholds drive diagnostic ordering in the Ascites Market?**
A: A serum-ascites albumin gradient of at least 1.1 g/dL points to portal hypertension, while a neutrophil count above 250 cells/mm³ confirms spontaneous bacterial peritonitis [1]. These cut-offs keep cell count and albumin assays on every diagnostic tap order.

**Q: Why do hospital buyers prefer concentrated albumin after paracentesis?**
A: Concentrated 20–25% solutions exert roughly five times the colloid-osmotic effect of plasma with a lower electrolyte load than 4–5% solutions [16]. Smaller infusion volumes also reduce sodium and fluid burden in patients already overloaded.

**Q: What precedent should investors weigh for intraperitoneal antibodies in the Ascites Market?**
A: Catumaxomab won EU approval for malignant ascites in 2009, but its marketing authorisation was withdrawn in 2017 for commercial reasons [24]. Approval alone did not secure uptake, so in the Ascites Market pricing and oncologist workflow matter as much as efficacy.

**Q: How does sodium restriction guidance affect oral therapy demand?**
A: Guidance pairs a 2 g/day sodium limit with spironolactone and furosemide in a 100:40 mg ratio [1]. This keeps generic oral diuretics high in volume but low in value, limiting branded competition across the Ascites Market.

**Q: Where should device suppliers focus first in the US?**
A: About 90 US liver transplant centres perform 95% of the country's liver transplants [10]. Concentrating Ascites Market sales teams there reaches most refractory patients with the fewest accounts.

**Q: Does shunt stent design influence procurement decisions?**
A: Covered PTFE-lined stents deliver better long-term patency than bare-metal stents and are the consensus standard for shunt creation [3]. Controlled-expansion designs let operators tune diameter to lower hepatic encephalopathy risk.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/ascites-market-1909*
